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Abstract 
Objective:  To compare the in vitro elution characteristics of six common analgesic 
medications from a commercially available absorbable gelatin sponge.  
Study Design:  Experimental study. 
Methods:  Gelatin sponges were loaded with various analgesic medications, including 
two opioids, preservative-free morphine and fentanyl, two local anesthestics, bupivacaine and 
lidocaine, and two α2-adrenergic agonists, dexmedetomidine and xylazine.  The loaded sponges 
were placed in dishes containing phosphate-buffered saline (PBS) and maintained at 37° C with 
constant agitation.  Concentrations of each drug were determined at various time points up to 24 
hours post-inoculation using high-pressure liquid chromatography.  Two phases were conducted, 
utilizing undried loaded sponges (phase one) and dried loaded sponges (phase two). 
Results:  In both phases, all analgesic medications eluted from the gelatin sponge and 
equilibrated rapidly with the PBS, achieving maximal concentration within 30 minutes.  In phase 
two, the rapid nature of the release was captured by increasing sampling within the initial 30 
minutes.  Results were consistent for each medication with minimal variation.  Steady state 
concentrations were significantly higher in phase two with four out of six medications. 
Conclusions:  Analgesic medication elution from an absorbable gelatin sponge was rapid 
and consistent.  Drying the loaded sponge prior to use will likely substantially increase the 
amount of medication eluted but not prolong release.    
Clinical Relevance:  The rapid release of analgesic medications from the gelatin sponge 
makes a prolonged analgesic effect unlikely without further modification.  Toxicity may be a 
concern.  Further study is required to investigate efficacy in vivo, safe dosing regimens and 
prolongation of duration of action. 
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CHAPTER 1 -  
Systemic versus regional drug administration 
 
The ability to deliver measured amounts of a substance continuously over an extended 
period of time to a local environment has advantages over systemic administration.  Such local 
delivery allows administration of lower volumes of medications, reduces or eliminates potential 
adverse effects, and achieves higher drug concentrations at the target tissue1-5.  Appropriately 
selected topical, local and regional techniques have been investigated for providing analgesia to 
veterinary patients while minimizing physiologic insult.  Drugs which are unable to be used 
systemically due to severe toxicity may be administered regionally due to lower systemic 
concentrations.  Theoretically nearly any drug could be administered via regional delivery 
instead of systemic, and many have been evaluated.  In most situations, regional drug 
administration promotes a longer duration of therapeutic action than intravascular or 
intramuscular administration, as these more traditional methods typically are rapidly distributed 
and metabolized6.  When administered orally, many drugs commonly undergo first-pass 
metabolism and biotransformation at the liver which inactivates the molecule, which is 
summarily excreted via renal, biliary or fecal routes46.  Preferably regionally-delivered drugs 
would exert their local effects the first time the drug reaches the target tissue, as once the drug 
leaves the target tissue and enters systemic circulation, behavior and efficacy are similar to 
systemic administration.  Many factors which will be further discussed in this manuscript, both 
relating to the drug and the in vivo environment, determine the pharmacokinetic and 
pharmacodynamic properties of each drug in an individual patient. 
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Disadvantages of common regional drug delivery systems include the expense, 
invasiveness, expertise and equipment often required to prepare and implement these techniques.  
Controlled-release systems are often intricately and meticulously created in a laboratory setting, 
making them impractical and cost-prohibitive for use in a typical veterinary clinical setting.  In 
nearly all situations, these devices require at a minimum heavy sedation and often general 
anesthesia for implantation, frequently in conjunction with major surgical procedures.  
Depending on the type of delivery, an additional hospital visit and anesthetic event may be 
necessary to remove the device and eliminate persistent adverse effects.  Standardizing the rate 
and duration of drug release as well as minimizing the patient’s immune response in vivo are 
vitally important to efficacy.  Implants can predispose the local surgical site to inflammation, 
tissue reaction and infection, and these risks must be addressed and minimized.  Another limiting 
factor in utilizing certain delivery systems is establishing the necessary technical expertise and 
obtaining the equipment required to perform these techniques7. 
Based on the discussed advantages and disadvantages of regional drug delivery, the ideal 
delivery vehicle would be biocompatible, absorbable, reproducible, inexpensive, practical for in-
hospital use, and structurally consistent with a functional porosity from which to elute drugs.  
Scientists and engineers have strived to attain these vehicle characteristics for many years, but 
few if any have achieved the production of an ideal delivery vehicle.           
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Delivery Vehicles 
 
The most common drugs investigated for regional elution in both the human and 
veterinary medical realms are antimicrobials8-14,16,28,29,33,34,37,38,123.  This phenomenon has been 
most extensively explored in both prophylactic and therapeutic models, using a variety of 
vehicles with varying levels of success.  The first description of regional antibiotic delivery was 
by Buchholz and Englebrecht in 1970, who described the elution of gentamicin and other 
antibiotics from polymethylmethacrylate (PMMA) beads8.  Literally thousands of scientific 
studies have been performed since then, scrutinizing various modifications of PMMA and other 
biomaterials to maximize the benefits of these drug-release vehicles.  Interestingly, even with 
decades of research and significant financial investment, the PMMA beads originally described 
by Buchholz are very similar to those routinely used today, mainly in orthopedic applications.  In 
several in vitro veterinary studies, PMMA-antibiotic beads have been shown to elute various 
antimicrobials with concentrations at least attaining minimum inhibitory concentration (MIC) 
over several weeks9-11.  The choice of which antimicrobial to combine with the PMMA is 
dependent on clinical experience, drug stability and culture and sensitivity results.  Because these 
antibiotics are eluted regionally and typically do not achieve high systemic concentrations, 
antibiotics which may not have been safe to use systemically become viable options with this 
route.  One example is aminoglycosides which have known systemic limitations due to renal 
tubular toxicity, but often can be beneficial for multidrug-resistant infections9,10.  Regional 
administration via PMMA beads often dramatically decreases the quantity of antibiotic required 
as compared with systemic administration which facilitates utilization of more expensive 
antibiotics such as meropenem, which otherwise might not be financially feasible in veterinary 
medicine11.  One major disadvantage of PMMA implants is the requirement for surgical removal 
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as they are not absorbable.  In addition, if the indication for PMMA-antibiotics beads is 
treatment of osteomyelitis and the beads are placed within an osseous defect, bone healing 
cannot occur until the PMMA is extracted. 
 Another biomaterial evaluated for use as an antibiotic delivery vehicle is calcium sulfate, 
or plaster of Paris.  Advantages include osteoconductivity and absorbability, obviating later 
surgical removal.  Calcium sulfate has been shown to neither stimulate nor inhibit bone 
formation12.  In an in vitro experimental study evaluating elution from calcium sulfate beads 
impregnated with either vancomycin, amikacin or both, only the vancomycin-impregnated beads 
were effective at inhibiting growth of a Staphyloccocus species for an extended period of time, 
up to 56 days12.  In this study, amikacin elution occurred over the 84 day study period but only 
achieved MIC for less than 24 hours.  Another study investigated a more rapidly absorbing 
calcium sulfate pellet impregnated with gentamicin demonstrated complete dissolution of pellets 
within 12-16 hrs which corresponded with 50-70% of antibiotic eluted within 4 hrs2. 
 With the recent advent of interventional radiology and stenting procedures in both human 
and veterinary fields, drug-eluting implants have been developed.  Especially in the 
cardiovascular realm, the risk of infection becomes paramount as catastrophic infectious 
complications occur in more than 25% of aortic prosthesis cases13,123.  Commercial knitted 
polyester grafts have been modified by immersing the graft in a gelatin sealant loaded with 
rifampin and tobramycin.  These modified aortic grafts have been shown to resist infection by 
Staphylococcus aureus in an in vivo canine model14.  Besides infection, another complication 
encountered with coronary arterial stenting is chronic inflammation and hypersensitivity 
reactions, potentially leading to thrombosis and restenosis4,15.  In an attempt to minimize the 
inflammatory response, coronary stents coated with a bioabsorbable polymer coating of salicylic 
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acid and sirolimus have been shown to elute these medications rapidly over the initial 48 hrs, 
followed by a gradual release over the following 6 days15.  However, localized overdose has 
been seen in cases of stent fracture4.  Self-assembled monolayers (SAMs) are polymers 
approximately 1-10 nm thick which are developed on a molecular level and added onto 316L 
surgical steel; various medications have been attached and, in one in vitro study with ibuprofen, 
demonstrated steady elution over a 35 day duration4.   
 The ophthalmic route of drug administration has also been developed, both for 
ophthalmic and systemic drug use.  One study, aimed at developing a novel treatment for 
endophthalmitis, evaluated a custom-made biodegradable polymer scleral plug which was 
impregnated with vancomycin, amikacin and dexamethasone16.  When assessed in vitro, the 
device eluted efficacious concentrations of the antibiotics for up to 14 days, and results 
suggested that potential methods to prolong the elution period included decreasing the 
antibiotic/steroid to polymer ratio, increasing the sintering temperature and/or increasing the 
compression pressures during device manufacture16.  Another study evaluating a custom polymer 
ophthalmic device found that elution was diffusion controlled and was altered by the pH of the 
eluent and the molecular weight and charge of the eluted drug17.  Using an equine recurrent 
uveitis model, Bilger et al. demonstrated prolonged release of cyclosporine and control of 
disease utilizing a custom-made biodegradable polymer pellet implanted surgically in the deep 
scleral tissue124.    
 In human and veterinary neurosurgery, application of a biomaterial to laminectomy sites 
has become standard of care.  This procedure was initially thought to decrease the likelihood of 
formation of fibrous adhesions and potential compression and/or pain between incised 
musculature healing adjacent to dura mater, the so-called laminectomy membrane18,19.  Materials 
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utilized include subcutaneous adipose tissue autograft, cellulose membranes, absorbable gelatin 
sponge and various gels.  Since these materials were being placed in the peridural region, 
researchers became interested in the addition of analgesic drugs to be subsequently eluted for 
therapeutic purposes.  The most extensively investigated human product is Oxiplex® gel 
(FzioMed Inc, San Luis Obispo, CA), which is an absorbable combination of 
carboxymethylcellulose and polyethylene oxide utilized to prevent epidural fibrosis, although not 
approved by the United States FDA.  In one small prospective human study conducted in Italy, 
morphine was mixed with Oxiplex® and applied epidurally in conjunction with microdiscectomy, 
leading to dramatically decreased pain scores for approximately 24-36 hrs, but worsening of pain 
after that time frame20.  Due to the apparent lack of prolonged analgesia, the authors could not 
recommend clinical use.  Another material utilized to deliver prolonged spinal analgesia is a 
viscous lidocaine-hyaluronate formulation which was demonstrated in a canine model to 
significantly prolong absorption kinetics, with an apparent half-life of 56 min versus 4 min for 
lidocaine solution21.  Unfortunately, this change in lidocaine absorption did not correlate with an 
increased duration of action as measured by loss of hindlimb motor function.    
Gelatin has been extensively investigated as a medium for drug delivery, and is produced 
by partial hydrolysis of collagen.  A multitude of studies have investigated various derivatives of 
this substance for drug delivery.  One commonly available absorbable gelatin sponge (Vetspon, 
Novartis Animal Health US, Inc., Greensboro, NC) is prepared from purified pork skin gelatin 
and is routinely used as a hemostatic agent in surgical procedures due to its ability to absorb and 
hold within its interstices up to 45 times its weight of fluid22.  Its use in the surgical site is well 
tolerated due to relatively fast absorption (four to six weeks in soft tissues) and lack of 
inflammatory or toxic side effects22.  Complete implant absorption avoids the surgical trauma 
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and anesthesia associated with physical extraction.  Studies have shown that these sponges have 
minimal cytotoxic and genotoxic characteristics and effectively induce platelet adhesion and 
release of α-granules in the formation of platelet aggregates23.   
The release of drugs from commercially available gelatin sponges as well as custom-
made sponges has been explored.  Utilizing a canine tracheomalacia model, scientists from Japan 
used commercial absorbable gelatin sponges impregnated with both basic fibroblast growth 
factor (bFGF) and bone morphogenetic protein (BMP-2) to slowly elute these substances into 
cartilaginous defects over several weeks and demonstrated significant improvements in 
regeneration compared with controls24-26.  Gelatin sponges used in a rabbit ulnar osteotomy 
model to elute BMP-2 led to 33% faster bone healing times than controls with either no sponge 
or saline-impregnated sponges27.  A similar study using a canine tibial osteotomy model 
illustrated improved bone healing when gelatin sponges impregnated with rhBMP-2 were placed 
at the osteotomy117.  The elution kinetics of commercial sponges are frequently altered by 
performing various sponge modifications.   
 
 
Gelatin sponge modifications 
 
Gelatin sponges have been utilized for many regional drug delivery systems, and most are 
either custom-made laboratory preparations or modifications of commercially available sponges.  
The most common challenges encountered when using commercial sponges to elute drugs are 
excessively rapid release of the drug and quick deterioration of the sponge material28,29.  
Strategies to retard drug elution include slowing the absorption of release medium, delaying the 
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release of drug molecules from the vehicle, and slowing the outward diffusion away from the 
vehicle into the local environment.  
The most effective approach to prolonging drug elution appears to be the addition of 
various diffusion restrictors to the gelatin sponge construct.  By crosslinking gelatin with alginate 
(a polysaccharide found in brown algae cell walls), prolonged drug release over four days was 
achieved in one study, which corresponded with decreased sponge porosity and decreased water 
uptake ability30.  Another study illustrated a slower penetration of eluent medium into the deeper 
portions of a gelatin sponge with the addition of polyethylene glycol monostearate and cetyl ester 
wax31.  These diffusion restrictors not only slowed water absorption, but simultaneously 
prevented rapid outward elution of drug as well.  Takemoto et al. created a collagen and gelatin 
sponge scaffold to facilitate sustained elution of bFGF, finding that varying the percentage 
composition of gelatin had a direct effect on duration of drug release32.  By coating these 
sponges with a thin silicone membrane, diffusion was further prolonged32.  Other intensely 
technical modifications which have demonstrated positive effects include blending chitosan 
(byproduct of chitin) or fibrin with gelatin, plasticizing sponge constructs, adding polyelectrolyte 
complexation between molecules, crosslinking matrices to decrease permeability, implanting 
drug-loaded gelatin microspheres, increasing collagen content, adding hydroxyapatite or other 
minerals, and altering drug molecule solubility, among others3,33-40.     
 Ophthalmic preparations have been shown to elute insulin and pilocarpine via scleral 
absorption, delaying release of these drugs compared with traditional liquid eyedrop 
administration41,42.  In both of these studies, loaded gelatin sponges were dried by evaporation 
under vacuum for at least 72 hrs prior to implantation to remove the solvents and possibly 
prolong drug elution41,42.      
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Epidural analgesia via gelatin sponge 
 
Many different epidural analgesics have been considered for use in human spinal surgery 
and delivered via several methods which are described in the epidural administration section of 
this manuscript.  The most common indication for spinal surgery in dogs is intervertebral disc 
disease and subsequent compressive radiculopathy, and numerous therapeutic variations of 
discectomies and laminectomies have been described.  One study in humans evaluated the 
feasibility of using a morphine- and methylprednisolone-impregnated gelatin sponge for 
postoperative analgesia following lumbar discectomy1.  Patients with this treatment option 
required significantly less postoperative parental narcotics, and were discharged from the 
hospital sooner than historical control patients not receiving the sponge1.  Few complications 
were noted, including intermittent bladder catheterization and presumptive discitis1.  Another 
study in humans evaluating the efficacy of buprenorphine-soaked gelatin sponges following 
thoracolumbar laminectomy illustrated a significant difference in pain relief scores 
postoperatively when compared with saline-soaked controls43.  In addition, the duration of pain 
relief until supplemental analgesia was requested was significantly longer in study patients, 
approximately 15 hours, when compared with controls at less than one hour43.  Side effects were 
minimal, although the study group experienced a higher incidence of nausea43.   
A similar study was performed by Domnick et al. investigating the efficacy of a 
medetomidine and preservative free morphine-impregnated gelatin sponge on postoperative 
analgesia following hemilaminectomy for thoracolumbar intervebral disc disease in dogs44.  This 
double-blinded prospective analysis demonstrated a significant analgesic effect of the 
impregnated sponge, as measured by pain scoring and rescue analgesic requirements45.   
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It should be noted that leaving an absorbable gelatin sponge in a peridural location is 
against the manufacturer’s recommendations, presumably for the concern of spinal compression 
as the sponge absorbs fluid and expands22. 
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CHAPTER 2 -  
Analgesic drug pharmacokinetics 
 
Several important factors determine the changing concentrations of a drug within an 
animal.  One of the critical factors which affects the concentration of active drug at the receptor 
site is plasma protein binding affinity.  Only drug which is free within the plasma can exit the 
extracellular fluid space and diffuse across membranes.  Clinically, albumin is the most common 
protein to which drugs bind, α1-acid glycoprotein (AAG) is the second biggest contributor, and 
others include globulins, mucopolysaccharides, hemoglobin, nucleoproteins and phospholipids.  
This binding process is usually reversible, and as unbound or free medication is excreted or 
diffuses out from the plasma, the weak chemical forces of the remaining albumin-drug complex 
are overcome to release additional free drug and restore the concentration of free drug circulating 
in the plasma46,47.    
A normally functioning and anatomically-intact glomerulus should not allow albumin to 
pass, thus exposing only unbound drug to the possibility of renal clearance by filtration.  A 
similar effect is appreciated in the hepatic parenchyma, as only unbound drug is able to diffuse to 
biotransformation sites46.  Thus, increased protein-binding may decrease hepatic metabolism and 
maintain plasma concentrations as well as prolong duration of action of the drug.  Different 
drugs have variable affinities for plasma albumin, and those with higher affinities can displace 
those with lower affinities, but clinical consequences are rare.  
Hypoalbuminemia and hypoproteinemia are common sequelae to a plethora of disease 
processes, and significant decreases in albumin and other plasma proteins can have a profound 
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effect on circulating drug concentrations.  Especially with highly protein bound drugs, the more 
severe the hypoalbuminemia, the greater the free drug concentration.  This could lead to 
prolonged or increased drug effect, and could predispose to toxicity issues that would not be of 
concern in euproteinemic states.  However, it may also lead to greater elimination.    
Diffusion of drugs across biological membranes is an important process which facilitates 
drug absorption, distribution, metabolism and excretion.  The rate and degree of absorption is 
dependent on the physiochemical properties of the drug (size, conformation, pH, pKa, solubility), 
the vehicle in which it is released, and on the biochemical nature of the membranes to be 
crossed46.  The influence of pH on diffusion is not completely understood, but the ionized form 
of a drug is usually more water soluble (hydrophilic) and less lipid soluble, making diffusion 
across the cell membrane less likely46.  On the contrary, non-ionized substances more readily 
cross the phospholipid bilayer.  The non-ionized to ionized drug ratio is dependent on the drug 
pKa, or dissociation constant, and the pH of the medium.  With drugs that undergo renal 
elimination, urinary pH can affect clearance.  In the face of alkaline urine, basic drugs tend to 
exist in the non-ionized form, thus are more lipid soluble and more likely diffuse back into the 
vasculature48.  Alkaline urine leads to ionized forms of acidic drugs, and consequently increased 
excretion.  The opposite phenomenon exists if acidic urine is present.  In addition, acidic drugs 
preferentially bind to albumin, while basic drugs tend to bind lipoproteins or α1-glycoproteins or 
both48. 
Volume of distribution is another variable which often has a dramatic effect on the 
pharmacokinetics of a drug.  Apparent volume of distribution is defined as the theoretical 
volume of fluid in which the total amount of drug administered would need to be uniformly 
distributed to achieve the desired plasma drug concentration49.  Larger volumes of distribution 
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are commonly found with lipophilic drugs, as these drugs easily diffuse and accumulate in body 
tissues, especially adipose tissue.  Prolonged release of drug from these stores may be 
appreciated.  Drugs which are hydrophilic and/or highly protein-bound are less likely to diffuse 
across cell membranes to access adipose stores, thus tend to have lower volumes of 
distribution49.   
Another pharmacokinetic variable to consider is clearance, which is defined as the 
volume of plasma cleared of drug by metabolism and excretion per unit time.  Clearance 
correlates precisely with the quantity of milliliters of the volume of distribution cleared per unit 
time.  Several variables can affect clearance, including protein binding, glomerular filtration rate, 
hepatic disease, afferent blood flow to the kidney, renal tubular reabsorption rate and others.  
Utilizing the two parameters of clearance and volume of distribution enables the half-life of a 
drug to be calculated, which is essential for clinical decision making.  Decreased renal function, 
increased drug protein binding and increased drug volume of distribution are three examples of 
situations which may lead to a drug half-life being significantly prolonged46,48.      
Morphine sulfate is a pure opioid agonist which acts at the μ and κ receptors.  It is a 
hydrophilic molecule with a pH of 2.5 to 6.0 for a solution of morphine sulfate.  It exhibits 
relatively low protein binding (36%), with higher skeletal muscle tissue binding observed at 
approximately 54%50.  The drug also concentrates in the renal, hepatic and pulmonary 
parenchyma, with lower levels found in the central nervous system when administered 
systemically.  Metabolism consists mainly of hepatic glucuronidation, and these metabolites are 
subsequently eliminated via renal excretion51.  Morphine is absorbed when given by 
intramuscular, intravenous, epidural and subcutaneous routes.  When administered orally, 
morphine is poorly and unreliably absorbed and likely undergoes significant first-pass 
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metabolism, substantially reducing bioavailability to approximately 5-18%52,53.  Similarly, when 
morphine is administered per rectum, only 19.6% becomes systemically bioavailable, making 
this route unlikely to be clinically efficacious54.  When administered intravenously in dogs, 
apparent volume of distribution is 4.5-7.5 L/kg, clearance is 62-83 mL/min/kg, and elimination 
half-life is approximately 1.1 hr50,53.  The plasma profile appears to correlate with a two 
compartment model, with a rapid initial distribution and subsequent slower elimination phase53.  
When administered via the epidural route, morphine is rapidly absorbed into the systemic 
circulation and detectable in the serum within five minutes, reaching a maximal concentration 
within 30-40 minutes55.  The elimination half-life of morphine from the lumbar CSF following 
epidural administration is approximately 3.5 hrs56.  Interestingly, cerebrospinal fluid (CSF) 
morphine levels following lumbosacral epidural injection achieve maximal concentrations 
sooner at the lumbar subarachnoid space than the cerebellomedullary cistern, at 60 minutes and 
180 minutes, respectively55,57.  Morphine appears in much higher concentrations in CSF than in 
plasma when administered epidurally, with a CSF: plasma concentration ratio of about 100-
20058.  A custom-made multivesicular liposome-based preparation of morphine administered via 
epidural catheter dramatically extended duration of efficacy, leading to a 17-fold increase in CSF 
mean residence time and three-fold increase in elimination half-life56.  Potential mechanisms 
responsible for the delayed CSF absorption are discussed later in this manuscript in the epidural 
administration section.   
Fentanyl citrate is a highly lipophilic phenylpiperidine derivative with a pH of 4.0 to 7.5 
in solution.  It is a full opioid agonist with activity at the μ receptor and is at least 100 times more 
potent than morphine.  It is highly protein bound.   Routes of administration include intravenous, 
intramuscular, epidural and transdermal.  Plasma fentanyl concentrations decrease rapidly for 
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approximately 20 minutes following intravenous injection due to redistribution throughout 
adipose and muscle tissue and elimination from the central compartment, exhibiting a short 
distribution half-life of 4.5 min59.  This rapid initial concentration decrease is followed by a more 
gradual decline as the drug is redistributed and eliminated from the body, thus best fitting a two 
compartment model59.  Fentanyl is metabolized via hydroxylation and N-dealkylation in the 
liver, and these metabolites are predominantly eliminated by the kidney, with less than 10% 
excreted in the feces60.  When administered intravenously, apparent volume of distribution is 
about 3-5 L/kg, clearance is 10-20 mL/min/kg, and elimination half-life is approximately 45 min 
to 4 hrs59.  Studies evaluating epidurally-administered sufentanil demonstrated vastly higher 
concentrations in CSF than those in plasma (44-fold), yet a shorter terminal elimination half-life 
in CSF of 2.8 hrs, compared with 4.1 hrs in plasma61,62. 
Lidocaine is an amide-type local anesthetic which acts at fast sodium channels inhibiting 
recovery after repolarization, and lidocaine solution has a pH of 6.5.  Routes of administration 
include intravenous, intramuscular, subcutaneous, local, transdermal and epidural.  Intramuscular 
administration is highly effective, with 91.9% of the dose absorbed, but in a clinical setting, 
regulating and monitoring dosing is more difficult than intravenous administration63.  Oral 
dosing is ineffective due to high first-pass effect.  Lidocaine undergoes plasma protein binding 
based on drug concentration, with the fraction of unbound drug increasing as overall drug 
concentration increases63.  Approximately 60-80% of lidocaine is protein bound, particularly to 
AAG, and this relationship can be dramatically affected by inflammatory disease states, with 
AAG increasing during the acute-phase response, and by cytokines, prostaglandin E2 and cyclic 
adenosine monophosphate64.  A significant negative correlation exists between the fraction of 
unbound lidocaine and AAG concentrations, such that increasing AAG concentrations as seen 
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with inflammation lead to decreased percentage free lidocaine65.  Metabolism occurs rapidly in 
the liver as biotransformation via oxidative N-dealkylation, ring hydroxylation, conjugation and 
cleavage of the amide linkage, producing metabolites which are eliminated in the urine.  
Approximately 10% of lidocaine is excreted unchanged in the urine63.  Following an intravenous 
bolus, the terminal elimination half-life is about 48 min, the mean specific clearance is 
approximately 1.2-2.4 L/kg/hr and the apparent volume of distribution is 4.5 L/kg21,63.  Severe 
hepatic dysfunction can lead to a prolonged lidocaine half-life.  Epidural administration of 
lidocaine appears to instigate a biphasic absorption process, with an initial fast phase exhibiting 
an apparent half-life of 4 min, followed by a slower absorption phase with a half-life of 131 
min21.   
Bupivacaine is a local anesthetic with a similar mechanism of action as lidocaine, 
although with a slower onset and longer duration of action.  It has a pH of 4.0 to 6.5 in solution 
and is more lipophilic than lidocaine, contributing to its longer duration of action and increased 
potency (four fold).  An intermediate hepatic extraction ratio of 0.38 may contribute to prolonged 
effect, compared with lidocaine’s hepatic extraction ratio of 0.6566.  Routes of administration 
include subcutaneous, epidural, intra-articular and intradermal69.  It is approximately 95% 
protein bound, and achieves high concentrations in highly perfused organs such as liver, brain, 
heart and lungs.  Metabolism occurs in the liver via dealkylation and hydrolysis, as well as 
partial detoxification by conjugation with glucuronic acid67.  This could lead to clinically 
significant toxicity in cats or patients with hepatic dysfunction due to limited capability to 
produce glucuronide conjugates67.  Excretion occurs through the kidney, with only 6% of 
bupivacaine excreted unchanged.  When administered with a short (15 min) intravenous infusion, 
the terminal half-life was about 53 min, clearance was about 9.5 mL/min/kg, and apparent 
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volume of distribution was 0.7 L/kg68.  A three-compartment open model appears to be in effect, 
with the first compartment represented by rapid distribution to highly perfused tissues such as 
brain, liver, kidneys, and myocardium, followed by equilibration of drug to the deep 
compartment of muscle, fat, skin and gastrointestinal tract68.  The third compartment represents 
elimination and redistribution from deep compartments.  Epidural administration has been shown 
to be a highly effective adjunct modality of analgesia with few side effects and a prolonged 
duration of action70-74, becoming efficacious within 2 minutes and having an elimination half-life 
of nearly three hours75.   
Xylazine is an α2-adrenergic agonist with sedative, analgesic and muscle relaxant 
properties.  It is a lipophilic compound with a pH in solution of 5.5, and it is generally 
administered via intravenous, intramuscular, epidural or subcutaneous routes.  After 
intramuscular administration, xylazine is rapidly absorbed and has a half-time of absorption of 
3.4 min, although absorption can be quite variable and incomplete, with a bioavailability 
between 52-90% in the dog76.  Following a single intravenous dose, the apparent volume of 
distribution is 2.5 L/kg, clearance is 81 mL/min/kg and the half-life of elimination is 24-30 
min76,77.  The pharmacokinetic data from these studies best fit a two-compartment open model.  
Xylazine undergoes rapid metabolism at the liver via conjugation and hydrolysis yielding about 
20 metabolites which are mostly excreted in the urine, and less than 8% is excreted in the urine 
unchanged78,79.  Epidurally administered xylazine has been shown to have a potent analgesic 
effect likely of local spinal origin in dogs, as analgesia was not impaired by administration of the 
α2-adrenergic antagonist atipamezole80,81.  Prospective studies have demonstrated that epidural 
xylazine administration decreases the minimum alveolar concentration of isoflurane in a dose-
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dependent manner in anesthetized dogs and is associated with minimal cardiovascular side 
effects82,83.                  
Dexmedetomidine is the most potent α2-adrenoceptor selective agonist available in 
veterinary medicine.  It is not a pure α2 agonist as it also binds noradrenergic imidazoline 
receptors found in the brain, kidney and pancreas, potentially leading to hypotension and anti-
arrhythmogenic action84,85.  It can be administered via the intravenous, intramuscular, epidural 
and transmucosal routes, while subcutaneous administration is not recommended due to erratic 
absorption and unreliable response86.  It is lipophilic and in solution has a pH of 4.5 to 7.087.  For 
many years, medetomidine was the major commercially available detomidine-related sedative 
used in small animal practice, with the majority of the α2-adrenoceptor activity from its d-
enantiomer, dexmedetomidine.  Only within the past two years was dexmedetomidine available 
commercially in veterinary medicine.  As demonstrated in receptor binding studies, 
medetomidine has an α2:α1 selectivity factor of 1620, which is significantly more selective than 
detomidine at 260, clonidine at 220 and xylazine at 16088.  Dexmedetomidine undergoes hepatic 
biotransformation via glucuronidation, hydroxylation, N-methylation and hydrolysis with 
subsequent excretion in the urine.  A small amount of metabolites is excreted in the feces and 
less than 5% excreted unchanged in the urine89.  Pharmacokinetic parameters of intravenous 
medetomidine include an apparent volume of distribution of approximately 3.0 L/kg, clearance 
of about 27-33 mL/min/kg, and terminal half-life ranging from 0.97 to 1.6 hrs89.  When given 
intramuscularly in dogs, peak plasma levels are achieved in about 35 min with 60% 
bioavailability, apparent volume of distribution is 0.9 L/kg, and elimination half-life is 
approximately 40-50 min86.  Kuusela et al. compared the pharmacokinetic parameters of 
medetomidine, dexmedetomidine and levomedetomidine in dogs and found very little difference 
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between medetomidine and dexmedetomidine, while the L-enantiomer had a significantly larger 
volume of distribution at steady-state and a more rapid clearance90.  Interestingly, the clinical 
effect of dexmedetomidine was similar but slightly more intense and longer acting than 
equipotent doses of medetomidine, while levomedetomidine appeared to be pharmacologically 
inactive.  The authors suggested this phenomenon could exist if the L-enantiomer interacted with 
or even antagonized the dextro-form, competed at the same receptor sites, or exhibited an effect 
on α1-receptors90. Several studies have illustrated the efficacy and duration of action of 
epidurally administered medetomidine and dexmedetomidine for prolonged analgesia, often in 
combination with an opioid91-94.                 
 
 
Epidural administration 
 
Analgesic drugs administered via the epidural route have been successfully utilized in 
both human and veterinary patients119-122.  Traditional methods of administration include spinal 
needle placement into the epidural space at the lumbosacral intervertebral space or caudal lumbar 
vertebrae, preferably avoiding intrathecal deposition.  Alternatively an epidural catheter can be 
placed at the lumbosacral space using palpation, or radiographic or fluoroscopic guidance.  
Analgesic drugs can also be administered directly to the dura mater as a local splash block or 
within a delivery vehicle in association with surgical procedures. 
Goals of epidural administration include decreasing or eliminating the need for systemic 
analgesia, decreasing the amount of general anesthetic medications necessary during surgical 
procedures, and providing potent pain relief directly at the level of the spinal nociceptive fibers.  
Additionally, minimizing or avoiding systemic adverse effects and reducing voluntary motor 
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function deficits are preferred.  The specific fibers involved in impulse transmission have been 
extensively investigated, and consist of nociceptive (C and A-δ), sympathetic (B), motor (A-α) 
and tactile sensory (A-β) fibers5,118.  Several factors influence the rapidity, duration and degree of 
blockade on these fibers, including the size and myelination of each fiber type, which affects 
medication diffusion5. 
Epidurally administered drugs are absorbed and distributed via at least four distinct 
processes:  transdural absorption into the cerebrospinal fluid and pia mater, sequestration by 
epidural adipose tissue, lymphatic uptake, and systemic absorption through the epidural 
vasculature and spinal radicular arteries57,95.  The degree of absorption with each route is highly 
dependent on the relative lipophilicity or hydrophilicity of the drug.  Highly lipophilic drugs will 
be absorbed rapidly in the vasculature and have systemic (supraspinal) effects, as well as a 
slightly prolonged effect likely from sequestration within the epidural fat95.  Hydrophilic drugs 
undergo minimal vascular uptake and thus have a longer mean residence time in the epidural 
space and prolonged elimination half-life, leading to increased spinal effects and less pronounced 
systemic effects96,97.  Spinal absorption of epidurally-administered drug requires movement 
through the meninges, which is mediated by the measured permeability coefficient.  Bernards 
and Hill scrutinized which factors influenced a certain drug’s coefficient, including molecular 
weight, molecular surface area, molecular volume, length of the major molecular axis, and 
octanol:water distribution coefficient, and found only the latter to have any correlation98.  A 
potential explanation for the biphasic relationship between hydrophilicity and the permeability 
coefficient involves the two layers of the meningeal barrier.  The arachnoid mater has both a 
hydrophilic aqueous region with extra- and intracellular fluid and a hydrophobic lipid domain 
with cell membrane lipids which need to be traversed to access the pia mater98.  Hydrophilic 
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drugs dissolve rapidly to penetrate the aqueous region, but have difficulty diffusing at the lipid 
interface.  Conversely, lipophilic drugs readily traverse the phospholipid bilayer but encounter 
the aqueous phase on the opposite side, thus encountering the rate-limiting step in diffusion96,97.  
For example, only 0.3% of epidural morphine is estimated to be able to cross the meninges due 
to the drug hydrophilicity57.  The octanol:buffer7.4 distribution coefficients for the drugs we 
analyzed are fentanyl 955, morphine 1.0, lidocaine 110, bupivacaine 560, dexmedetomidine 2.8, 
and xylazine 0.15, with a higher coefficient correlating with increased lipophilicity5. 
The specific gravity of CSF and the administered drug affect the distribution of drug 
throughout the subarachnoid space.  Normal canine CSF ranges between 1.005 and 1.017 and 
feline CSF between 1.005 and 1.0215.  In humans, hyperbaric drugs tend to spread caudally 
toward the lower spine, while hypobaric drugs spread rostrally against gravity5.  Most drugs 
administered epidurally are hypobaric, such as morphine (1.002) and bupivacaine (1.003), or 
isobaric, such as lidocaine (1.010)5.  When epidural opioids are administered, diffusion rates 
through the spinal meninges and rostral spread to the thoracic spine are inversely related to the 
drug molecular weight96-98. 
The μ, κ and δ opioid receptors are present in elevated concentrations in laminae I and II 
of the dorsal horn of the spinal cord99.  When bound, these G-protein-linked receptors inhibit 
intracellular cAMP and voltage-gated calcium channels resulting in prevention of substance P 
release from C and A-δ nociceptive fibers, which subsequently inhibits ascending transmission 
via excitatory pathways to the brain.  Opioids induce minimal blockade of B-sympathetic, A-α 
and A-β fibers, thus having little to no effect on vascular tone, motor, and tactile sensory 
modalities, respectively5. 
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Local anesthetic medications act by blocking voltage-gated sodium channels in the nerve 
membrane, thus inhibiting the generation and propagation of action potentials.  Because these 
channels are present in all nerve fibers, preferential blockade is not possible.  Nerve fibers differ 
substantially in their susceptibility to blockade, as well as the onset and duration of effects, due 
to nerve fiber size and myelination.  In general, smaller shorter fibers (B and C) are blocked 
before larger fibers (A) fibers, and unmyelinated fibers are blocked before similarly sized 
myelinated fibers5,67.  The order of blockade seen clinically is B, C, A-δ, A-γ, A-β and A-α, 
corresponding to pain, warmth, touch, deep pressure and motor function, respectively5,100.  In 
addition to lipid solubility, pKa has also been shown to affect the rate of penetration of a drug 
through lipid membranes100.  Three important effects that local anesthetics have on axonal 
excitability include: tonic impulse depression leading to conduction failure, as sub-blocking 
concentrations lead to progressive decreases in excitability until conduction is halted; use-
dependent conduction failure, where the axon’s capability to propogate action potentials is 
inhibited by the presence of local anesthetic-bound sodium channels; and activity-dependent 
suppression of impulses101.   
Spinal α2-receptors initiate several mechanisms in a similar fashion to opioids, including 
blockage of substance P release from C nociceptive fibers, presynaptic binding on primary 
afferent terminals, and postsynaptic action on dorsal horn neurons91.  Sensory blockade via C and 
A-δ fibers occurs, as well as moderate tactile sensory and mild motor blockade.  Systemic α-
effects can be quite dramatic depending on drug dose and distribution, but B sympathetic fibers 
are not directly affected.  Xylazine has to been shown to have an isoflurane sparing effect when 
administered epidurally83, and epidural medetomidine and dexmedetomidine have significant 
antinociceptive effects in cats102 and dogs92.  Several studies have suggested that epidural α2-
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agonist administration may potentiate epidural opioid analgesic effects91,103.  Branson et al. 
demonstrated in a canine tail clamp model that a single dose of medetomidine administered 
epidurally had minimal analgesic effect alone, but when combined with morphine, more than 
doubled the duration of analgesia compared with morphine alone91.  Similar results were seen in 
a tail withdrawal reaction test in rats, where epidural medetomidine was found to have minimal 
intrinsic antinociceptive effects, but produced significant potentiation of analgesia with epidural 
fentanyl104.  A similar synergistic interaction with opioids was demonstrated with epidural 
morphine and medetomidine in dogs anesthetized for cranial cruciate ligament stabilization105. 
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CHAPTER 3 - Experimental Study 
 
PURPOSE 
 
The purpose of this study was to compare the drug release characteristics of six common 
analgesic medications from a commercially available absorbable gelatin sponge in vitro, and 
extrapolate this data to determine the feasibility of a future in vivo prospective clinical study 
utilizing a mammalian surgical model.  We hypothesized that the absorbable gelatin sponge 
would elute analgesic medications at a consistent, rapid rate which could be quantified in vitro. 
 
MATERIALS AND METHODS 
PHASE 1 
Absorbable gelatin sponges were cut into approximately 10x20x7 mm pieces from 
commercially available slabs.  The mass of each sponge was determined prior to drug addition.  
The mass of a sponge of the aforementioned dimensions was 0.0197 g, and to minimize 
variability, each sponge was trimmed until it weighed within 2.5% of this mass (range 0.0192 to 
0.0202 g; mean 0.0197 g; SD 0.0003).  Five milliliters of each of six medications was placed into 
a six milliliter glass test tube.  Medications evaluated included two opioid medications, 
preservative-free morphine sulfate (Duramorph, Hospira, Inc., Lake Forest, IL) (25 mg/ml) and 
fentanyl citrate (Fentanyl citrate, Hospira, Inc., Lake Forest, IL) (50 μg/ml), two local 
anesthestics, bupivacaine hydrochloride (Bupivacaine HCl, Hospira, Inc., Lake Forest, IL) (5 
mg/ml) and lidocaine hydrochloride (Lidocaine HCl, Hospira, Inc., Lake Forest, IL) (20 mg/ml), 
and two α2-adrenergic agonists, dexmedetomidine hydrochloride (Dexdomitor, Pfizer Animal 
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Health, New York, NY) (0.5 mg/ml) and xylazine hydrochloride (AnaSed, Lloyd Laboratories, 
Shenandoah, IA) (100 mg/ml).  Each of the different drugs was assessed in triplicate.  Each 
sponge was completely immersed in the specific medication for five seconds, squeezed entirely 
to expel air bubbles, and immediately replaced in the test tube.  After soaking for one hour, the 
sponges was carefully removed with thumb forceps and placed directly in an individual petri dish 
filled with twenty milliliters of sterile phosphate-buffered saline (PBS) at pH 7.4.  The medium 
was maintained at pH 7.4, 37° C and constantly agitated throughout the study.  The PBS was 
sampled at 0, 0.5, 1, 2, 4, 8, 12 and 24 hours by removal of 200 microliters of the eluent fluid.  
After each sample was collected, 200 microliters fresh PBS was added, and each test tube was 
returned to the agitator.  The collagen sponges were not rinsed with PBS between transfers to 
more closely approximate physiologic conditions.  Eluent samples were immediately frozen and 
stored at -70˚ C.  Concentrations of each drug were determined in triplicate via high-pressure 
liquid chromatography (HPLC) with UV detection or HPLC with mass spectrometry as detailed 
below.     
 
PHASE 2 
Phase two was similar to phase one with the exception of altering sponge loading  and 
timing of sample collection.  Due to the high concentrations of xylazine observed in phase 1, the 
concentration of xylazine in phase two was 20 mg/mL.  Instead of immersing the sponges in 
each analgesic medication for one hour, the sponges were loaded by placing the test tubes with 
the sponge and five milliliters of each medication in an evaporator unit (TurboVap LV 
evaporator, Zymark Inc., Portland, OR).  This unit subjected the test tubes to continuous air flow 
(15 psi) and a warm water bath (37° C) until the medications had evaporated and the sponges 
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were visibly dry.  This loading phase took between 24 and 36 hours.  The loaded sponges were 
then placed in PBS as previously described in phase one.  Eluent samples were collected at the 
following time points: 0, 10, 20, 30, 45, 60 and 90 minutes and 2, 4, 8, 12 and 24 hours.  
 
Determination of drug concentrations in PBS 
The concentrations of fentanyl (m/z 337.14 →105.3), dexmedetomidine (m/z 201.231 
→95.1), and morphine (m/z 286.08 → 152.1) were determined using liquid chromatography with 
mass spectrometry. The internal standard solution contained fentanyl d5 (m/z 342.158 → 105.0) 
100 ng/mL for fentanyl, ondansetron (m/z 294.206 → 170.3) 1000 ng/mL for dexmedetomidine, 
and morphine d6 (m/z 292.13 → 151.90), 1000 ng/mL for morphine in 50% methanol. Standard 
solutions were made in PBS. The analyte ranges were 0.1-10.0 µg/mL for fentanyl, 1.0 - 50.0 
µg/mL for dexmedetomidine, and 1.5625 – 50.0 µg/mL for morphine. Standard curves were 
constructed daily and run at the beginning and the end of the sample batches and accepted if the 
predicted value was within 15% of the actual concentration and the correlation coefficient (R) 
was at least 0.99. The sample preparation for fentanyl consisted of adding 25 µL of the sample or 
standard and 50 µL of the internal standard solution to 425 µL 0.1% formic acid and vortexed. 
The sample preparation for dexmedetomidine consisted of adding 50 µL of the sample or 
standard and 50 µL of the internal standard solution to 400 µL 0.1% formic acid and vortexed. 
Due to the high concentrations of morphine in all samples, they were initially diluted by adding 
20 µL of the sample to 980 µL PBS. The diluted samples or standards, 20 µL, were added to 50 
µL of IS and 930 µL of 0.1% formic acid. The mobile phase consisted of A: acetonitrile and B: 
0.1% formic acid at a flow rate of 0.4 mL/min. A gradient starting at 100% B from 0-1 minute, 
then a linear gradient to 80% B at 3 minutes which was held until 6 minutes, then a linear 
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gradient to 100% B 6.5 minutes with a total run time of 7.5 minutes. The column used was a C18 
column (Supelco Discovery 2.1x50 mm, 5.5 µM, Sigma, St. Louis, MO, USA). 
Lidocaine, bupivacaine and xylazine were measured by HPLC with UV detection. 
Lidocaine and bupivacaine standards and samples were prepared by adding 10 µL to 990 of 
0.05% trifluroacetic acid. The standard curve for lidocaine was linear from 0.125 – 2 mg/mL, for 
bupivacaine from 0.03125 – 1 mg/mL, and for xylazine from 0.3125 – 10 mg/mL. Standard 
curves were accepted if the predicted concentration was within 15% of the actual concentration 
and R>0.99. The UV absorption was monitored at 203 nM for lidocaine and 215 nM for 
bupivacaine and xylazine. The mobile phase consisted of A: acetonitrile and B: 0.02% TFA at a 
flow rate of 1 mL/min. The mobile phase for lidocaine, bupivacaine and xylazine were 82% B, 
70% B, and 78% B, respectively. 
The resultant data were evaluated with a regression analysis.  Statistical analysis was 
performed using repeated measures ANOVA.  P<.05 was considered significant for all statistical 
calculations. 
Based on the structural variation observed when cutting the gelatin sponges to size, we 
used sponge mass to minimize variability.  We then evaluated the relationship of sponge mass to 
sponge volume with unused, unloaded gelatin sponges.  Twenty sponges were cut into 
rectangular prisms weighing precisely 0.0200 g.  The linear dimensions of these sponges were 
then measured in millimeters using a surgical ruler (Kendall Devon skin marker & ruler, Tyco 
Healthcare Group LP, Mansfield, MA) to simulate a type of measurement device routinely 
available in a surgical environment.  The volume of each sponge was then calculated in cubic 
millimeters using the formula V= length x width x height.      
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RESULTS 
In phase one, all analgesic medications eluted from the gelatin sponge and equilibrated 
rapidly with the PBS (Figure 1).  Results were consistent for all medications, with minimal 
variation within each trial.  Maximal concentration of each medication was achieved within 30 
minutes for all medications.   
In phase two, maximum elution also occurred by 30 minutes (Figure 2).  By increasing 
the sampling frequency within this initial 30 minute period, we were able to capture the rapid 
nature of this release.  Results were again consistent for all medications, with a similarly minimal 
amount of variation within each trial.   
Steady state concentrations were achieved within two hours in both phases, and were 
significantly higher in phase two than in phase one with four out of six medications.  The mean 
steady state concentration of fentanyl in phase two was 8.37 µg/mL, which was significantly 
higher than the mean steady state concentration of 1.45 µg/mL in phase one (p<.001) (Figure 6).  
The mean steady state concentration of lidocaine in phase two was 2718 µg/mL, which was 
significantly higher than the mean steady state concentration of 554.9 µg/mL in phase one 
(p<.001) (Figure 3).  The mean steady state concentration of bupivacaine in phase two was 729.9 
µg/mL, which was significantly higher than the mean steady state concentration of 208.7 µg/mL 
in phase one (p<.001) (Figure 4).  The mean steady state concentration of dexmedetomidine in 
phase two was 60.4 µg/mL, which was significantly higher than the mean steady state 
concentration of 22.5 µg/mL in phase one (p<.001) (Figure 8).  In contrast to the other 
medications, the mean steady state concentration of xylazine in phase one was 4966.4 µg/mL, 
which was significantly higher than the mean steady state concentration of 964.5 µg/mL in phase 
two (p<.001) (Figure 7).  The difference in xylazine concentration, five-fold, is similar to the 
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difference in concentration used in phase one (100 mg/mL) and phase two (20 mg/mL).  The 
mean steady state concentration of morphine was 664.7 µg/mL in phase one and 720.3 µg/mL in 
phase two, which were not significantly different (p=.18) (Figure 5).  The sponges remained 
intact throughout the sampling in phase one, but in phase two, some of the dried sponges broke 
apart when transferred.      
Twenty gelatin sponges each weighing precisely 0.0200 g had volumes ranging from 
1260 to 1540 mm3.  The corresponding linear width dimension of each sponge was quite 
variable, ranging from 9 to 11 mm, while the height and length were consistently 7 mm and 20 
mm, respectively. 
 
DISCUSSION 
A method to deliver controlled amounts of analgesic medications in a local environment 
is desirable for a number of reasons.  Decreased systemic side effects, decreased medication 
quantities, and potential increased efficacy can be seen with such a delivery technique1-5.  Having 
an inexpensive, practical local analgesic option rapidly available during the immediate 
perioperative period would be beneficial to veterinary surgeons.  Various delivery devices have 
been investigated for a plethora of medications with mixed results.  The most commonly used 
compounds to elute medications in veterinary surgery are polymethylmethacrylate and calcium 
sulfate beads, often placed in infected surgical environments to elute antibiotics over weeks to 
months9-12.  Several morphine-eluting gels and pastes have been investigated for use in human 
spinal surgery, with mixed results regarding analgesic efficacy and prevention of post-surgical 
scarring20,106-110.  Recently, some veterinary surgeons have augmented their standard post-
operative hemilaminectomy pain protocol with the addition of an analgesic-impregnated gelatin 
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sponge placed peridurally within the hemilaminectomy window44.  This modification anecdotally 
improved patient comfort, and prospective clinical analysis of this technique appears 
promising45.  To the authors’ knowledge, elution of veterinary analgesic medications from an 
absorbable gelatin sponge has not been quantified.  We chose two medications from each of the 
following classes: μ-opioid receptor agonists (fentanyl, morphine), α2-adrenoceptor agonists 
(dexmedetomidine, xylazine) and sodium-channel blocking local anesthetics (lidocaine, 
bupivacaine).  The results of this pilot study confirm that analgesic medications were eluted from 
an absorbable gelatin sponge at a consistent, albeit rapid, rate.    
The concentration of each medication appeared to be directly related to the eluted steady 
state concentration achieved.  Fentanyl, the medication with the lowest concentration used to 
load the sponges (0.05 mg/mL), achieved the lowest steady state concentration (1.45 µg/mL).  
As the concentration of the medication increased, the corresponding steady state concentration 
achieved was higher.  This applied for all medications sampled in phase one, with the most 
concentrated medication, xylazine at 100 mg/mL, achieving the highest steady state 
concentration at 4966.4 µg/mL.  In phase two, this effect was similar with the three least 
concentrated medications: fentanyl, dexmedetomidine and bupivacaine, respectively.  However, 
the most concentrated medication, morphine at 25 mg/mL, did not achieve the highest steady 
state concentration.  This was achieved by lidocaine (20 mg/mL) with a mean steady state 
concentration of 2718 µg/mL.  The reason for this result is unknown, although variable drug 
stability while exposed to light and increased temperatures during evaporation, or differing 
affinities of each medication for the gelatin sponge may be factors.        
By drying the loaded sponges before insertion into the elution medium, significantly 
higher steady state concentrations were consistently achieved compared with undried sponges.  
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This effect was seen with fentanyl, lidocaine, bupivacaine and dexmedetomidine.  In contrast to 
these medications, significantly greater steady state concentrations were achieved with undried 
sponges than with dried sponges when utilizing xylazine.  This is very likely the result of the 
altering of the concentration of xylazine used to load the sponges between phases one and two, 
with 100 mg/ml solution utilized for phase one and 20 mg/ml solution for phase two.  This 
change in xylazine concentration between phases was made because of the massive absolute 
quantity of xylazine eluted in the first phase.  Toxicity concerns would be a major factor, as 
discussed further in the next paragraph.  If the same concentration of xylazine was used for both 
phases, a similar effect may have been seen.  Assuming a linear relationship existed between the 
drug concentration and the steady state concentration achieved, we would have expected a five-
fold increase in steady state xylazine concentrations in phase two if the 100 mg/ml solution had 
been used instead of the 20 mg/ml solution.  The steady state concentration of morphine was not 
statistically significant between phases. 
When quantifying the eluent concentrations of all medications, toxicity concerns become 
readily apparent.  For example, the steady state concentration of xylazine achieved in phase one 
was approximately 5 mg/ml, which equates to approximately 100 mg of drug eluted from each 
sponge.  This total quantity of xylazine would likely have a substantial potential for toxicity, 
especially in small animals.  Xylazine administration using this concentration and vehicle could 
have profound and potentially lethal consequences, as recommended doses range from 0.5 to 2.2 
mg/kg in dogs86.    Even larger dogs weighing 30 to 40 kg would be overdosed with this 
protocol.  Depending on the level of systemic absorption and distribution, described side effects 
of xylazine include emesis, muscle tremors, bradycardia, bradypnea, and even fatal cardiac 
arrest111,112.  The toxic effects of lidocaine have also been extensively investigated in animals, 
 32 
 
with concerns arising at serum levels above 8 µg/mL in dogs113-116.  Described adverse effects 
include central nervous system stimulation, muscle tremors, ataxia, depression, nystagmus, 
hypotension, bradycardia (PR and QRS interval prolongation), seizures and circulatory 
collapse86.  Similar toxicity concerns could exist with all medications, especially if utilizing 
loaded sponges prepared as in phase two, as significantly greater mean steady state 
concentrations of eluted medication are achieved.  Critical evaluation of these variables with in 
vivo pharmacokinetic and pharmacodynamic analyses as well as establishment of efficacious 
dosing regimens would be prudent prior to clinical implementation.         
Unfortunately, achieving prolonged elution was not accomplished.  By drying the 
analgesic-loaded sponge prior to placement in the medium, we were able to achieve higher 
steady state concentrations but the speed of elution was not altered.  Further modifications of the 
gelatin sponge may be considered to prolong medication elution.  In one study investigating 
ophthalmic pilocarpine release from Gelfoam, researchers were able to extend release for five 
hours by impregnating the sponge with two diffusion restrictors, cetyl ester wax and 
polyethylene glycol 400 monostearate, which are relatively inexpensive and nonirritating 
substances31.  By embedding the sponge with these retardants using an extensive production 
protocol, prolonged drug elution may be attained by slowing release medium penetration and 
simultaneously preventing rapid outward diffusion of the drug.  Other techniques known to 
change the local elution kinetics from collagen-based matrices include cross-linking the matrix to 
decrease permeability, increasing collagen content, and making the drug molecule less water 
soluble37.  According to the manufacturer, a gelatin sponge will absorb completely in four to six 
weeks when placed in an appropriate environment22.  Thus, it appears that achieving prolonged 
release beyond this time frame is unlikely without significant vehicle modifications. 
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The gelatin sponge device we utilized is composed of a network of interstitial pores 
which allow release medium to rapidly penetrate the matrix interior.  We hypothesize that the 
eluent quickly penetrated the pores and dissolved the medication, with the medication 
subsequently diffusing throughout the external PBS.  The rate at which eluent penetrates the 
sponge is dependent on the tortuosity of the pores, the sponge density, solubility and diffusion 
coefficient in the solvent31.  In phase one, this process appears to have occurred instantaneously.  
Our first sampling point was 30 minutes, and additional sampling within the initial 30 minutes 
may have revealed differences between each medication elution rate.  However, these potential 
differences within the initial 30 minutes would be highly unlikely to be clinically relevant.  In 
phase two, we adjusted our sampling times to further scrutinize the drug release kinetics with 
focus on the first hour.  The release was again rapid for all medications, although sampling 
points within the first hour demonstrated an exponential release curve with maximal steady state 
concentrations achieved after approximately one to two hours.  
Determination of the time to onset and duration of action for medications delivered into a 
wound environment is likely multifactorial, involving surface area, volume and porosity of the 
delivery device, volume and concentration of the eluted medication, relative lipo- or 
hydrophilicity of the medication, eluent fluid turnover rate in the local environment, and pH and 
temperature of the environment.  Relative lipophilicity and hydrophilicity did not seem to affect 
the elution rate in our study.   Fentanyl is a highly lipophilic drug, while morphine is relatively 
hydrophilic, and the elution pattern was identical.  This finding suggests that the medication 
lipophilicity did not affect binding to the gelatin sponge nor dissolution in the release media.  It 
is unknown whether this variable would influence elution in a closed in vivo situation. However, 
a local environment with a low fluid turnover rate may lead to prolonged elution.   
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The relationship of sponge mass to sponge surface area and volume is variable as 
demonstrated by the aforementioned results.  It appeared that the structural integrity of each 
sponge was variable, and the effects of these inconsistencies are unknown.  The seemingly rapid 
penetrability and relative porosity of the gelatin sponge suggest that sponge mass and volume 
may not have an appreciable impact of elution rates, while these measurements may be a more 
determinant factor in mean steady state concentrations or the total amount of medication eluted.  
If used clinically, maintaining a precise sponge size may be important to minimize variability.     
The medications investigated in this study are commonly utilized for postoperative 
analgesia.  Potential applications for this vehicle include post-operative hemilaminectomy and 
other spinal surgery, limb or digit amputation, radical reconstructive procedures 
(mandibulectomy, hemipelvectomy) and many more.  In addition, delivered medications would 
not be limited to analgesia alone.  Impregnating a gelatin sponge with antibiotics may be possible 
for placement within an infected wound environment or a location where systemically 
administered antibiotics may not penetrate well.   
One of the potential limitations with this study was the use of phosphate buffered saline 
instead of bovine serum, which would more closely imitate physiologic conditions.  We believe 
that elution was unlikely to be affected by using PBS, and many drug elution studies have 
utilized PBS as the eluent2,4,9-12,17.  Differing drug protein-binding affinities would be apparent 
when using serum, but this variable is more likely to affect distribution and elimination in vivo, 
and unlikely to affect drug elution in vitro.  During phase two, several dessicated sponges broke 
into several pieces when transferred from the evaporating test tube to the elution medium.  This 
structural change and increase in sponge surface area could have affected drug elution, although 
did not appear to have this effect in the present study.  In addition, variable amounts of 
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crystallized medication were present on the surface of each sponge, potentially altering the 
resulting concentrations.  Although unlikely, it is possible that further medication was eluted 
beyond 24 hours, which would not have been recognized with our study design and clinically 
insignificant due to lack of sustained elution throughout the initial 24 hours.  During sponge 
preparation, it was noted that gross structural inconsistencies existed within as well as between 
each sponge.  Because of this, we decided to utilize mass which would more accurately reflect 
the quantity of microscopic interstices for each sponge to minimize variation.  Exact geometric 
dimensions were not calculated, although each sponge was prepared in approximately 
rectangular cuboid fashion.  
This study confirms that the absorbable gelatin sponge has potential for use as a delivery 
vehicle for analgesic medications.  The relatively low cost of these commercially-available 
products makes them attractive compared with other expensive custom-made delivery matrices.  
However, the immediate release of these medications calls into question the practicality and 
duration of efficacy of this model in veterinary surgical patients.  In addition, potentially toxic 
doses of analgesic medications could be eluted in an in vivo situation.  Without further 
modification of the sponge to reliably extend drug release, we cannot recommend clinical use at 
this time.  Further studies are necessary to determine if other alterations of the sponge-drug 
preparation technique will appropriately prolong drug elution while maintaining the practicality 
and cost effectiveness desired in veterinary surgery.  In addition, prospective clinical trials are 
needed to ascertain analgesic efficacy and establish safe dosing regimes.     
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